|
3.2 Prévention - Obésité
|
|
|
Linda Bauld: Why we need to keep talking about obesity and cancer [BMJ Blogs]
|
|
|
|
|
|
Smoking
rates didn’t come down on their own. The decline followed decades of
effort to raise awareness about the health risks, coupled with strong
policy action such as tobacco taxation, a ban on smoking in indoor
public places, removing tobacco marketing and more recently introducing
standardised packaging. Cancer Research UK aims to help tackle obesity
in a similar way, by pushing the government and food and drink industry
to act in the interests of public health.
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
TIL Therapy Explained by Steven Rosenberg, MD, PhD [AACR]
|
|
|
|
|
|
“The
methods utilized in this study represent a blueprint for the isolation
of T cells that can react against any type of cancer,” said Rosenberg.
“Because all cancers have mutations, the techniques that we’ve described
can potentially be used to identify T cells that react to mutations
that occur in any tumor.”
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
China’s Alphamab Oncology pulls off $100M series A [FierceBiotech]
|
|
|
|
|
|
It
has four programs in the clinic, including two bispecific antibodies,
according to the statement: KN046, an antibody that targets PD-L1 and
CTLA-4, and KN026, which targets HER2. Both are currently in phase
1—KN046 in Australia with multiple phase 1/2 trials to follow in China
and KN026 in China, with a second phase 1 study coming up in the U.S.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.12 Ethique
|
|
|
|
6.5 Médecines alternatives/complémentaires
|
|
|
Is there such a thing as the “placebome”? [Respectful Insolence]
|
|
|
|
|
|
It
has to be shown that there even is such a thing as the “placebome.”
That has yet to be demonstrated convincingly. What has been demonstrated
is that COMT alleles can be associated with differences in drug effects
and might—at best, might—be associated with more response to placebo.
It’s a lot of correlation, and no evidence for causation.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
Patient-driven efforts to liberate clinical cancer genomic data [OSF Preprints]
|
|
|
|
|
|
While
this experiment exposed multiple difficulties for patient genomic data
access, we argue that these difficulties can be overcome with a
patient-centered platform to facilitate these efforts. Toward that end,
we propose and describe a patient-driven cancer genome collective to
directly address this need and empower data liberation and donation to
advance cancer research and patient empowerment.
|
|
|
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|
Improved Grading of Prostate Cancer Using Deep Learning [Google AI Blog]
|
|
|
|
|
|
We
developed a deep learning system (DLS) that mirrors a pathologist’s
workflow by first categorizing each region in a slide into a Gleason
pattern, with lower patterns corresponding to tumors that more closely
resemble normal prostate glands. The DLS then summarizes an overall
Gleason grade group based on the two most common Gleason patterns
present.
|
|
|
|
|
|
|
|
6.9 Controverses
|
|
|
Failure: The Real Secret Sauce of Engineering [Omics! Omics!]
|
|
|
|
|
|
So
now the question: how do you analyze such a failure? When a bridge
fails one can look at footage of the failure, at the wrecked parts and
at design documents. One can look for clear structural alterations,
sloppy construction or environmental effects. But how could this be
applied to the IPI-926 pancreatic trial failure? Even if you could get
biopsies from every patient -- not an easy task given they would likely
all be post mortem - -what would you look for?
|
|
|
|
|
|